Dennis Cho Sells 5,000 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 5,000 shares of Twist Bioscience stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $49.93, for a total value of $249,650.00. Following the completion of the transaction, the insider owned 138,581 shares in the company, valued at $6,919,349.33. The trade was a 3.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Dennis Cho also recently made the following trade(s):

• On Tuesday, February 3rd, Dennis Cho sold 1,099 shares of Twist Bioscience stock. The shares were sold at an average price of $46.58, for a total transaction of $51,191.42.
• On Monday, December 22nd, Dennis Cho sold 324 shares of Twist Bioscience stock. The stock was sold at an average price of $34.56, for a total value of $11,197.44.

Twist Bioscience Stock Performance

TWST stock opened at $49.11 on Friday. The company has a market capitalization of $3.01 billion, a price-to-earnings ratio of -38.37 and a beta of 2.24. The firm has a 50 day moving average of $38.63 and a two-hundred day moving average of $32.47. The company has a quick ratio of 3.37, a current ratio of 3.78 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $51.00.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The company had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. The company’s revenue was up 16.9% compared to the same quarter last year. As a group, equities analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Twist Bioscience

Large investors have recently modified their holdings of the stock. Campbell & CO Investment Adviser LLC boosted its stake in Twist Bioscience by 227.6% in the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 47,200 shares of the company’s stock valued at $1,328,000 after buying an additional 32,792 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in Twist Bioscience by 14.5% in the third quarter. Thrivent Financial for Lutherans now owns 1,463,085 shares of the company’s stock valued at $41,171,000 after buying an additional 184,726 shares in the last quarter. Baillie Gifford & Co. increased its holdings in Twist Bioscience by 62.8% during the 3rd quarter. Baillie Gifford & Co. now owns 1,262,739 shares of the company’s stock valued at $35,533,000 after purchasing an additional 487,052 shares in the last quarter. New York State Common Retirement Fund raised its position in Twist Bioscience by 14.0% in the 3rd quarter. New York State Common Retirement Fund now owns 584,694 shares of the company’s stock valued at $16,453,000 after purchasing an additional 71,777 shares during the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of Twist Bioscience by 13.2% during the second quarter. American Century Companies Inc. now owns 864,384 shares of the company’s stock worth $31,801,000 after purchasing an additional 100,978 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Barclays increased their price objective on Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, February 3rd. Stephens initiated coverage on shares of Twist Bioscience in a research report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Robert W. Baird set a $50.00 target price on Twist Bioscience in a research report on Tuesday, February 3rd. Finally, Evercore upped their price target on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $45.88.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.